{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:04:29Z","timestamp":1761894269281},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T00:00:00Z","timestamp":1146009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1007\/s00277-006-0113-5","type":"journal-article","created":{"date-parts":[[2006,4,25]],"date-time":"2006-04-25T12:05:54Z","timestamp":1145966754000},"page":"530-534","source":"Crossref","is-referenced-by-count":20,"title":["Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"85","author":[{"given":"Frank","family":"Neumann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefani","family":"Harmsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Kronenwett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Kondakci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Aivado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Kobbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,4,26]]},"reference":[{"key":"113_CR1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1023\/B:JOCI.0000029108.18995.61","volume":"24","author":"M Berger","year":"2004","unstructured":"Berger M, Pinciaro PJ (2004) Flebogamma 5% investigators. Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 24:389\u2013396","journal-title":"J Clin Immunol"},{"key":"113_CR2","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","volume":"15","author":"W Brugger","year":"2004","unstructured":"Brugger W, Hirsch J, Grunebach F, Repp R, Brossart P, Vogel W, Kopp HG, Manz MG, Bitzer M, Schlimok G, Kaufmann M, Ganser A, Fehnle K, Gramatzki M, Kanz L (2004) Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 15:1691\u20131698","journal-title":"Ann Oncol"},{"key":"113_CR3","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","volume":"19","author":"JC Byrd","year":"2001","unstructured":"Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153\u20132164","journal-title":"J Clin Oncol"},{"key":"113_CR4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"key":"113_CR5","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2005.02.172","volume":"23","author":"MS Czuczman","year":"2005","unstructured":"Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH (2005) Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 23:694\u2013704","journal-title":"J Clin Oncol"},{"key":"113_CR6","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Bock HP, Wandt H, Unterhalt M, Hiddemann W, German Low-Grade Lymphoma Study Group (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064\u20133071","journal-title":"Blood"},{"key":"113_CR7","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","volume":"94","author":"AS Freedman","year":"1999","unstructured":"Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, Schlossman R, Alyea EP, Takvorian T, Jallow H, Kuhlman C, Ritz J, Nadler LM, Gribben JG (1999) Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325\u20133333","journal-title":"Blood"},{"key":"113_CR8","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule. Blood 103:4416\u20134423","journal-title":"Blood"},{"key":"113_CR9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","volume":"23","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF, Betticher DC, Schefer H, Pichert G, Stahel R, Ketterer N, Bargetzi M, Cerny T, Swiss Group for Clinical Cancer Research (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23:705\u2013711","journal-title":"J Clin Oncol"},{"key":"113_CR10","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","volume":"20","author":"JD Hainsworth","year":"2002","unstructured":"Hainsworth JD, Litchy S, Burris III HA, Scullin DC, Corso SW, Yardley DA, Morrissey L, Greco FA (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 20:4261\u20134267","journal-title":"J Clin Oncol"},{"key":"113_CR11","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","volume":"23","author":"JD Hainsworth","year":"2005","unstructured":"Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA (2005) Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23:1088\u20131095","journal-title":"J Clin Oncol"},{"key":"113_CR12","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","volume":"20","author":"OM Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20:1288\u20131294","journal-title":"J Clin Oncol"},{"key":"113_CR13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2003-04-1257","volume":"103","author":"SM Horwitz","year":"2004","unstructured":"Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE, Johnston LJ, Wong RM, Shizuru JA, Horning SJ (2004) Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103:777\u2013783","journal-title":"Blood"},{"key":"113_CR14","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","volume":"104","author":"G Lenz","year":"2004","unstructured":"Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, Hess G, Truemper L, Diehl V, Kropff M, Kneba M, Schmitz N, Metzner B, Pfirrmann M, Unterhalt M, Hiddemann W, German Low-Grade Lymphoma Study Group (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104:2667-2674","journal-title":"Blood"},{"key":"113_CR15","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/annonc\/mdg201","volume":"14","author":"J Mangel","year":"2003","unstructured":"Mangel J, Buckstein R, Imrie K, Spaner D, Franssen E, Pavlin P, Boudreau A, Pennell N, Combs D, Berinstein NL (2003) Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as \u2018in vivo purge\u2019 and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol 14:758\u2013765","journal-title":"Ann Oncol"},{"key":"113_CR16","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417\u20131423","journal-title":"Blood"},{"key":"113_CR17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1600-0609.2004.00391.x","volume":"74","author":"S Martin","year":"2005","unstructured":"Martin S, Fischer C, Free M, Kurreck B, Stockinger H, Fenk R, Arnold C, Kliszewski S, Meckenstock G, Haas R, Kronenwett R (2005) LightCycler\u00ae-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy. Eur J Haematol 74:282\u2013292","journal-title":"Eur J Haematol"},{"key":"113_CR18","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa031770","volume":"350","author":"N Milpied","year":"2004","unstructured":"Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL, Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287\u20131295","journal-title":"N Engl J Med"},{"key":"113_CR19","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","volume":"19","author":"SM O\u2019Brien","year":"2001","unstructured":"O\u2019Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Michael J, Keating MJ (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165\u20132170","journal-title":"J Clin Oncol"},{"key":"113_CR20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","volume":"10","author":"LD Piro","year":"1999","unstructured":"Piro LD, White CA, Grillo-L\u00f3pez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V (1999) Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol 10:655\u2013661","journal-title":"Ann Oncol"},{"key":"113_CR21","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Durk H, Rost A, Neise M, von Grunhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 23:3383\u20133389","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-006-0113-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-006-0113-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-006-0113-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T03:36:17Z","timestamp":1586835377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-006-0113-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,26]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["113"],"URL":"https:\/\/doi.org\/10.1007\/s00277-006-0113-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,26]]}}}